Aclaris Therapeutics ACRS Operating Lease Liabilities (Total)

Operating Lease Liabilities (Total) at other companies

Upstream Bio, Inc.UPB

$1.27M-30.8%

Avalo TherapeuticsAVTX

$242K-64.4%

Cullinan Therapeutics, Inc.CGEM

$2.07M+36.3%

AnaptysBio, Inc.ANAB

$13.61K-99.9%

Alumis Inc.ALMS

$35.66M+1,881%

ImmunityBio, Inc.IBRX

$40.77M+0.5%

FAQ

What is Aclaris Therapeutics's operating lease liabilities (total)?

Aclaris Therapeutics (ACRS) reported operating lease liabilities (total) of $1.85M in Q2 2026.

How has Aclaris Therapeutics's operating lease liabilities (total) changed year-over-year?

Aclaris Therapeutics's operating lease liabilities (total) decreased by 21.8% year-over-year, from $2.37M to $1.85M.

What is the long-term trend for Aclaris Therapeutics's operating lease liabilities (total)?

Over 5 years (2020 to 2025), Aclaris Therapeutics's operating lease liabilities (total) has grown at a -9.6% compound annual growth rate (CAGR), from $3.5M to $2.12M.

What does operating lease liabilities (total) mean?

This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.